Implandata Ophthalmic Products GmbH (Implandata) is a disruptive ophthalmic digital health company, located in Hannover, Germany.

With its CE marked EYEMATE™ system for remote monitoring and care of glaucoma patients, Implandata is going to transform the treatment of glaucoma. With 80 million patients at risk of permanent loss of eyesight due to glaucoma, Implandata is addressing an underserved medical need in a vast and further growing market. Implandata’s EYEMATE™ system enables eye care specialists to remotely manage their patients and personalize treatment in order to preserve glaucoma patients’ eyesight. Glaucoma patients are empowered via self-monitoring, resulting in improved therapy compliance and quality of life.

Initial investment:
2010

B2G Partner:
Günter Steffen

Milestones

Milestones

2010
Foundation and seed financing
2012
First-in-human pilot study
2014
Granting of key property rights and patents
2015
Multicentric clinical study for CE mark
2017
CE approval and post-market validation studies
2018
Strategic investor Heidelberg Engineering becomes shareholder
2019
CE mark expansion and market internationalisation
2020
Long-term product data demonstrates product safety and efficacy; NuB Reimbursement
2020
Start USA regulatory approval process

“B2G helped us at a decisive stage in the development of our business, with financial support and expertise, so that we were able to reach key milestones on the path toward marketing our product.”

Max Ostermeier
Founder and CEO